Cencora (NYSE:COR – Get Free Report) and XWELL (NASDAQ:XWEL – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.
Risk and Volatility
Cencora has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, XWELL has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Valuation & Earnings
This table compares Cencora and XWELL”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cencora | $321.33 billion | 0.21 | $1.55 billion | $7.95 | 42.91 |
| XWELL | $33.90 million | 0.11 | -$16.85 million | ($3.37) | -0.18 |
Cencora has higher revenue and earnings than XWELL. XWELL is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
97.5% of Cencora shares are owned by institutional investors. Comparatively, 8.7% of XWELL shares are owned by institutional investors. 10.8% of Cencora shares are owned by company insiders. Comparatively, 13.9% of XWELL shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Cencora and XWELL’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cencora | 0.48% | 227.15% | 4.30% |
| XWELL | -51.85% | -352.37% | -64.88% |
Analyst Recommendations
This is a summary of current ratings and target prices for Cencora and XWELL, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cencora | 0 | 4 | 8 | 1 | 2.77 |
| XWELL | 1 | 0 | 0 | 0 | 1.00 |
Cencora currently has a consensus target price of $373.25, suggesting a potential upside of 9.42%. Given Cencora’s stronger consensus rating and higher probable upside, equities analysts clearly believe Cencora is more favorable than XWELL.
Summary
Cencora beats XWELL on 13 of the 15 factors compared between the two stocks.
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
About XWELL
XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
